Schering-Plough Corp: A Castle Charity in the Medical Budget

In the Schering-Plough Corp FCPA case, the company agreed to a $500,000 civil penalty over allegations that its Polish operation used charitable payments to influence pharmaceutical purchases and recorded them inaccurately. The Securities and Exchange Commission described a castle-restoration charity, a president who ran a government health fund, and medical explanations sent to finance. If you knew why the business chose a particular charity, you could see something the donation entry left out.

The Securities and Exchange Commission announced the resolution on June 9, 2004. Its account of the allegations connected the recipient, the official’s purchasing influence and the company’s alleged accounting failures under the Foreign Corrupt Practices Act. The case turns on a familiar question inside a business: what was the payment really for?

The Charity and the Public Drug Buyer

Schering-Plough Poland’s payments allegedly bought influence over public pharmaceutical purchasing through the Chudow Castle Foundation. The foundation’s founder and president also directed the Silesian Health Fund, a Polish government body that provided money for medicines and influenced hospital purchases through its allocation of resources.

According to the Commission’s administrative order, the foundation was a genuine charity established to restore castles and other historic sites in Poland’s Silesian region. The first payment followed shortly after its founder took charge of the health fund.

The Commission said the Polish operation paid the foundation 315,800 zlotys, approximately $76,000, between February 1999 and March 2002. It alleged that the purpose was to induce the director to influence purchases of Schering-Plough products. The civil penalty addressed the alleged accounting and control violations behind those payments.

The corporate structure explains how a local donation became an accounting issue for the parent. Schering-Plough Corporation was headquartered in New Jersey, while the Polish operation was a branch of its wholly owned Swiss subsidiary, Schering-Plough Central East AG. The Commission said the payments were not accurately reflected in that subsidiary’s books and that the parent’s internal accounting controls were inadequate.

Medical Justifications for a Castle Foundation

The Securities and Exchange Commission described charitable payments with a commercial purpose supported by false medical explanations. In early 2000, the health fund director asked the Polish oncology unit manager for further contributions. The manager then arranged twelve additional payments through March 2002, according to the order.

The order described some payments structured at or below the manager’s approval limit, apparently to conceal their nature. The Commission also said the manager supplied false medical justifications for most payments on documents submitted to finance. The order’s payment table included this explanation:

Other entries described lung cancer prevention and skin cancer screening. Yet the Commission said the manager knew the foundation did not actually conduct healthcare programs. The foundation had told the company its bylaws permitted health programs. Permission on paper supplied no health campaign for these payments to fund.

We find that contrast hard to explain away: a castle charity in the recipient field, cancer prevention in the justification. The Commission’s account puts the person arranging the payments in possession of the information that made those descriptions false. That is why the manager’s knowledge matters alongside the form sent to finance.

The pattern also stood out inside the donation budget. The foundation received more promotional-donation money than any other recipient, accounting for approximately 40% of that budget in 2000 and 20% in 2001. It was the only recipient to receive repeated payments, according to the Commission. Someone reviewing the full recipient history would have seen a concentration that an individual approval form could not show.

Why a Health Fund Mattered to Drug Sales

The health fund’s power lay in financing and influencing purchases by institutions such as hospitals. In the Commission’s account, that made its director commercially important to Schering-Plough’s Polish business. The relationship reached the money behind the drug order.

The Securities and Exchange Commission enforcement director’s 2015 speech on pharmaceutical sales and internal controls explains the industry setting. Pharmaceutical representatives regularly deal with doctors, pharmacists and administrators at public hospitals, people who often decide which products public hospitals or pharmacies buy. The speech identified payments disguised as charitable contributions among recurring patterns in pharmaceutical foreign-bribery cases.

The Schering-Plough order also described a sales concentration. According to the Commission, sales of the oncology products Intron A and Temodal increased disproportionately in Silesia compared with other Polish regions during the payment period. By 2002, Silesia accounted for 53% of Intron A and 40% of Temodal sold in Poland.

For a sales insider, those figures place the donation relationship beside the business it allegedly sought to influence. Finance sees the expense and its explanation. The sales team may understand the public purchaser and the importance of its decisions. We connect those views because the commercial purpose can disappear when each department sees only its own part.

Books, Approval Limits and the Missing Check

The Commission’s books-and-records and internal-controls allegations concerned both the account of the payments and the system that allowed them. The Polish operation classified all the payments as donations. According to the order, the manager instead viewed them as dues required for the director’s assistance.

The missing check was specific. Before March 2002, Schering-Plough’s procedures did not require employees to investigate whether government officials were affiliated with proposed promotional or charitable recipients. The Commission said the Polish operation therefore never considered whether the director’s relationship to the foundation raised a foreign-bribery concern.

The recipient’s work, the approval history, the budget and the official relationship belonged together. A review limited to whether a form carried an authorized signature would leave the purpose of the payment unresolved. The Commission’s account shows why the explanation behind an approval can matter as much as the approval itself.

The Civil Settlement and the Controls Review

Schering-Plough agreed to the civil penalty in the Commission’s federal court case and settled the accompanying administrative proceeding. The administrative order required accurate books and adequate accounting controls, with an outside reviewer to examine those systems for compliance with the Foreign Corrupt Practices Act.

The order also said no Schering-Plough employee in the United States knew about or approved the foundation payments. The Commission nevertheless pursued the parent company over alleged accounting and controls failures. For someone inside an overseas operation, that distinction matters: the local approval trail and the parent’s system were both part of the case.

The Same Charity Connection in Healthcare Purchasing

Fresenius Medical Care supplies a close parallel involving charity connections and government orders. Its SEC administrative order alleged payments to a Saudi charity executive whose organization influenced government tender awards. The order reproduced an email in which a distributor’s general manager relayed the executive’s explanation of how charity support would secure government orders:

The Schering-Plough order’s account of dues and the Fresenius email expose the commercial expectation behind the charitable relationship. In each, the agency alleged a connection between the payment and influence over public purchasing. The recipient’s public purpose was only part of the business story.

The 2022 Journal of Forensic and Investigative Accounting paper Fresenius Medical Care: A Case Study on the FCPA concluded that managers and employees circumvented internal controls despite flagged transactions and existing policies. Its analysis gives an insider’s account of what happened after a warning particular weight. A policy describes the process the company says it follows. The payment history shows the decisions people actually made.

What an Insider Can Explain

In the Commission’s account, the donation justification, the recipient’s actual work and the manager’s commercial understanding told different stories. A finance employee may recognize the explanation that supported a payment, while a sales colleague may know why the official’s help mattered. Our whistleblower experts work with that business knowledge to connect the payment, the purpose and the people who authorized it.

We assess your information for foreign-bribery whistleblower rewards with FCPA whistleblower counsel who know pharmaceutical bribery cases. For separate fraud against the U.S. government, a whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know What the Donation Was For

If you saw medical justifications that did not match a charity’s work, or contributions tied to a public buyer, tell our whistleblower experts what the business expected from the payment. We develop the case with you, bring in foreign-bribery whistleblower lawyers who understand pharmaceutical purchasing and false accounting, and stay beside you throughout the process.